Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | European Journal of Clinical Pharmacology
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study - ScienceDirect
With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Laquinimod - an overview | ScienceDirect Topics
Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS | Neurology Neuroimmunology & Neuroinflammation
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva Pharmaceuticals - Wikiwand
Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model | Journal of Neuroinflammation | Full Text
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Laquinimod - an overview | ScienceDirect Topics
Laquinimod - Wikipedia
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
Form 10-K
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS | Neurology Neuroimmunology & Neuroinflammation
Cells | Free Full-Text | Laquinimod Supports Remyelination in Non-Supportive Environments
Laquinimod - an overview | ScienceDirect Topics
Active Bio and Teva's laquinimod strikes out again, this time in progressive MS | Fierce Biotech
Meet the Compound: Laquinimod – HD Insights
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study - The Lancet Neurology
425
425
Laquinimod - an overview | ScienceDirect Topics
Laquinimod - PharmaKB
Multiple Sclerosis Clinical Trial Update: Laquinimod
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS | Journal of Neuroinflammation | Full Text
